Actively Recruiting
Open-Label Study Evaluating Multiple Doses of LT3001 to Restore Arterial Blood Flow in Adults With Acute Ischemic Stroke
Led by Lumosa Therapeutics Co., Ltd. · Updated on 2026-10-22
10
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase II, open-label, single-arm study to evaluate the effect of multiple doses of the LT3001 drug product on reopening blocked arteries in adults who have experienced an acute ischemic stroke AIS. The goal is to assess intracranial arterial recanalization, which means restoring blood flow in the brain arteries after a stroke. Participants are also expected to receive standard care treatments for AIS when appropriate. Participants will receive multiple doses of LT3001 administered by intravenous infusion. The study will take place at multiple centers and involves imaging tests like computed tomography angiography CTA or magnetic resonance angiography MRA to confirm arterial blockage. The treatment is given within 24 hours after stroke symptom onset, and the study excludes those who have received certain stroke treatments like intravenous thrombolytics or endovascular thrombectomy. During the study, participants will undergo evaluations including brain imaging, stroke severity assessments using the NIH Stroke Scale NIHSS, and monitoring of arterial reopening 24 hours after the first dose. Safety and neurological function will be closely observed throughout the trial. The primary outcome measured is the rate of successful recanalization at 24 hours. The study lasts until completion in 2028, with participants involved through the treatment and follow-up periods.
CONDITIONS
Brief Title
A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant
Research Team
C
Claire Sun
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here